Canadian plan sponsors brace for a 65% semaglutide list-price cut once a third generic lands

Benefits analysts told Canadian plan sponsors to prepare for a 65% cut in semaglutide list prices once a third generic version of the drug reaches the market, according to reporting from GLP1Prices.^[1] The trigger is not the first generic approval but the arrival of a third competitor, under Canada's pan-Canadian Pharmaceutical Alliance (pCPA) pricing framework.^[1]

Under that framework, the first generic entrant is priced at 75% to 85% of the brand price. Once three or more generics are on the market, the price falls to 35% of brand, a 65% reduction from the original brand price.^[1] As of early August 2026, two generic semaglutide products, from Dr. Reddy's and Apotex, had already reached Canadian pharmacies, with Dr. Reddy's authorized on April 28.^[1] A site tracker cited in the reporting showed three of nine submitted generic semaglutide products approved by Health Canada, with additional files still under review.^[1]

Sandoz is now targeting the third quarter of 2026 to bring its version to market, and Aspen Pharmacare is pursuing a Canada-first launch strategy, according to the report.^[1] Separately, Health Canada's Drug Product Database listed Aspen-Semaglutide and a product called Sevmia as approved but not yet marketed as of July 28, 2026, meaning approval alone does not guarantee pharmacy availability.^[1] Health Canada also faced a broader backlog, with more than 500 generic drug submissions pending across all drug categories and at least seven semaglutide-specific files still awaiting decisions as of early August.^[1]

The opening for generic competition traces back to a patent decision. Patent expert Tahir Amin of I-MAK said Novo Nordisk could have extended its Canadian Ozempic patent until 2028 but did not renew it.^[1] A related report said Novo Nordisk stopped paying a roughly $250 annual patent maintenance fee in 2018, a lapse that ultimately allowed generic semaglutide to reach Canadian pharmacies in 2026.^[1] The BMJ reported that Canada became only the second country worldwide to approve a generic version of semaglutide.^[1]

Novo Nordisk has already begun responding commercially. The company launched a savings card for uninsured Canadians that aligns Ozempic's price with generic pricing, available through Rexall pharmacies in all provinces except Quebec.^[1] Novo Nordisk has forecast a 5% to 13% decline in 2026 global sales as Canadian generic competition and other pressures weigh on revenue.^[1]

Why it matters for patients

For Canadian patients and the employer-sponsored drug plans that cover many of them, the pCPA's three-generic threshold means budget relief could arrive in a single step rather than gradually. Once Sandoz or another manufacturer becomes the third generic entrant, plan sponsors could see list prices for semaglutide fall to roughly a third of the original brand price almost overnight.^[1]

The report frames this as a structural difference from the United States. Canada's tiered pricing rules automatically reset prices at defined generic-competition thresholds, a mechanism that does not exist in the US market, where employers and pharmacy benefit managers negotiate rebates and formulary placement drug by drug rather than through a centralized pricing trigger.^[1] That difference is one reason analysts expect Canadian GLP-1 spending to fall faster than spending in the US, even as both countries see new generic and lower-cost options enter the market.

For patients specifically, government approval of a generic does not always mean it is immediately available at a pharmacy, as shown by Aspen-Semaglutide and Sevmia sitting in approved-but-not-marketed status.^[1] Anyone comparing costs should also be aware that unauthorized or counterfeit GLP-1 products have prompted separate Health Canada warnings, a reminder that price and availability updates are moving quickly and unevenly across pharmacies and provinces.^[1]

What happens next

Sandoz is targeting the third quarter of 2026 to launch its generic semaglutide, which would be the third such product on the Canadian market and would trigger the 35%-of-brand pricing tier under pCPA rules.^[1] Health Canada continues to review additional generic semaglutide submissions, and it is not yet known from these sources exactly when Aspen's or Sevmia's products will reach pharmacy shelves.^[1]